Integrins are a family of proteins that sit on the surface of nearly every cell in your body, acting as the primary connection between a cell and its surroundings. They anchor cells to the structural scaffolding around them (called the extracellular matrix) and to other cells, while simultaneously relaying information in both directions across the cell membrane. In humans, 18 alpha subunits and 8 beta subunits combine to form 24 distinct integrin receptors, each tailored to recognize specific molecules outside the cell.
How Integrins Are Built
Every integrin is made of two protein chains: an alpha subunit and a beta subunit. These two chains pair together to form a single functional unit called a heterodimer. The pairing matters because it determines what each integrin can bind to on the outside of the cell and what signals it triggers on the inside. Some combinations specialize in gripping collagen fibers, others latch onto clotting proteins in the blood, and others connect immune cells to the walls of blood vessels.
The extracellular portion of the integrin extends outward like a bent arm, reaching into the surrounding environment to find its target molecule. The intracellular tail, which is relatively short, connects to the cell’s internal skeleton (the cytoskeleton) through a series of adapter proteins. This physical linkage is what gives integrins their dual role: they’re both an anchor and a communication line.
Two-Way Signaling
What makes integrins unusual is that they don’t just receive signals or send them. They do both, and the direction of information flow changes depending on what the cell needs.
In “outside-in” signaling, integrins detect what’s happening in the cell’s environment and pass that information inward. When an integrin binds to a molecule outside the cell, it triggers chemical signals that tell the cell where it is, what type of tissue surrounds it, and whether it should move, divide, or stay put. These signals also help the cell decide whether to survive or self-destruct, and they work alongside signals from growth factors and other receptors to shape the cell’s behavior.
In “inside-out” signaling, the process runs in reverse. The cell sends a signal to the integrin’s inner tail, which causes the protein to change shape on the outside. This shape change increases the integrin’s grip on its target molecule, essentially switching the integrin from a low-affinity “off” state to a high-affinity “on” state. A key protein called talin binds to the integrin’s inner tail, disrupting interactions between the alpha and beta subunits and triggering a conformational shift that propagates outward across the membrane. This activation mechanism is critical in situations where cells need to quickly ramp up adhesion, like when platelets rush to seal a wound.
Sensing Physical Force
Integrins don’t just respond to chemical cues. They also sense mechanical forces, converting physical tension into biochemical signals inside the cell. When external force is applied to an integrin, it can stretch into a more extended, high-affinity shape, strengthening its bond with the molecules around it. This has been observed in single-molecule experiments where pulling on an integrin causes it to unfold and bind more tightly.
Inside the cell, force-sensitive proteins like talin and vinculin change their own shape under tension, exposing new binding sites that recruit additional structural and signaling molecules. The result is a feedback loop: external force strengthens the adhesion site, which stiffens the cell’s internal skeleton, which in turn pulls harder on the integrin. This process, called mechanotransduction, is how cells respond to the stiffness of their environment. It explains, for example, why stem cells placed on a stiff surface tend to develop into bone cells, while those on a soft surface become fat cells.
The RGD Recognition Sequence
Nearly half of all known integrins recognize a specific three-amino-acid sequence in their target proteins: arginine-glycine-aspartate, abbreviated RGD. This short molecular tag appears in a wide range of adhesive proteins found in the extracellular matrix, in the blood, and on cell surfaces. It’s such a reliable binding signal that researchers can reproduce integrin binding using short synthetic peptides containing just the RGD sequence, a discovery that has driven decades of work in drug design and biomaterials engineering.
Other integrins recognize related but distinct sequences, which is part of how the 24 different integrin combinations achieve specificity. The particular combination of alpha and beta subunits determines not only which sequence the integrin prefers but also how tightly it binds and what downstream signals it activates.
Integrins in Blood Clotting
One of the best-studied integrins is the platelet integrin αIIbβ3, which is absolutely required for platelet aggregation. When you cut yourself, platelets must clump together to form a plug. That clumping depends on αIIbβ3 binding to fibrinogen (the protein that forms the mesh of a blood clot) as well as to other adhesive proteins like von Willebrand factor, fibronectin, and vitronectin.
In resting platelets, αIIbβ3 stays in its low-affinity state. It can stick to immobilized proteins on a damaged vessel wall, but it won’t grab soluble fibrinogen floating in the blood. Only after platelets are activated by injury signals does inside-out signaling switch αIIbβ3 to its high-affinity state, enabling it to capture fibrinogen and crosslink platelets into a stable aggregate. This activation step is what antiplatelet drugs target to prevent dangerous clots in arteries.
Integrins in Cancer
Tumors exploit integrins at multiple stages of their growth and spread. Cancer cells often overexpress certain integrins that promote invasion into surrounding tissue. One integrin in particular, αvβ5, has been shown to drive tumor cell invasion in many carcinomas.
Integrins also play a central role in angiogenesis, the process by which tumors recruit new blood vessels to feed their growth. Every step of new vessel formation, from breaking through the basement membrane to cell migration, proliferation, and tube formation, is regulated by integrins. The tumor microenvironment activates integrins on nearby blood vessel cells, promoting their migration and survival as they invade toward the tumor. Blocking specific integrins with antibodies can selectively inhibit this tumor-driven vessel growth without affecting existing blood vessels, which is why integrins remain an active area of interest for cancer therapy.
Beyond blood vessels, integrins help tumors build lymphatic drainage routes. Certain integrins on lymphatic cells bind directly to growth factors that promote lymphatic vessel formation, potentially giving cancer cells a pathway to spread to lymph nodes.
Diseases Caused by Integrin Defects
When integrins don’t work, the consequences are severe and often apparent from birth.
Glanzmann thrombasthenia is a bleeding disorder caused by mutations in the αIIbβ3 integrin. Without functional αIIbβ3, platelets cannot aggregate at all. People with this condition experience excessive bleeding from cuts, nosebleeds, and heavy menstrual periods because their platelets simply can’t stick together.
Leukocyte Adhesion Deficiency type 1 (LAD-I) results from mutations in the gene for the β2 integrin subunit. Immune cells called leukocytes rely on β2 integrins to grab onto blood vessel walls and migrate into infected tissue. Without them, leukocytes can’t leave the bloodstream effectively, leading to recurrent, life-threatening bacterial infections despite high white blood cell counts in the blood.
A rarer and more dangerous condition, LAD-III, combines features of both diseases. Children with LAD-III have normal integrin levels, but their integrins can’t be activated because of mutations in kindlin-3, a protein required for inside-out signaling. The result is both the bleeding problems of Glanzmann thrombasthenia and the immune deficiency of LAD-I. Affected infants typically present with brain hemorrhages at birth, delayed separation of the umbilical cord, and severe infections, requiring repeated blood transfusions.
Integrin-Targeting Medications
The importance of integrins in immune cell trafficking has led to FDA-approved drugs that block specific integrins to treat inflammatory diseases. Natalizumab and vedolizumab are both approved for the treatment of Crohn’s disease, and vedolizumab is also approved for ulcerative colitis. These drugs work by preventing immune cells from using their integrins to exit the bloodstream and enter the gut wall, reducing the inflammation that drives these conditions.
The two drugs differ in their specificity. Vedolizumab targets an integrin found mainly on gut-homing immune cells, which limits its effects to the intestinal tract. This gut-selective approach was a deliberate step toward reducing the risk of broader immune suppression. Antiplatelet drugs that interfere with αIIbβ3 represent another class of integrin-targeted therapy, used to prevent arterial blood clots in cardiovascular disease.